Loading...
Market
What will be the mean LVMI reduction achieved by Lexeo Therapeutics' LX2006 at 24 months by July 15, 2025?
2
Resolution / Starting Odds
Less than 15% • 25%
15% to 19.9% • 25%
20% to 24.9% • 25%
25% or more • 25%
Lexeo Therapeutics' official press releases or clinical trial publications
Story
Lexeo Therapeutics Reports Positive Interim Data for LX2006 with 18.3% LVMI Reduction at 18 Months
Jul 15, 2024, 10:03 AM
Lexeo Therapeutics has announced positive interim Phase 1/2 clinical data for its gene therapy, LX2006, aimed at treating Friedreich Ataxia Cardiomyopathy. The data revealed a mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at 18 months in participants who had elevated LVMI at baseline. Baird remains bullish on Lexeo, noting that levels approaching 20% would be a significant milestone. The Baird report suggests that the LX2006 update can provide further proof-of-concept. Despite some early data showing promise, there are concerns about the clarity of the results.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Mean weight loss < 5% • 25%
Mean weight loss 5% to 7% • 25%
Mean weight loss 7% to 9% • 25%
Mean weight loss > 9% • 25%
Less than 5% weight loss • 25%
5% to 10% weight loss • 25%
10% to 15% weight loss • 25%
More than 15% weight loss • 25%
Highly Effective • 25%
Moderately Effective • 25%
Minimally Effective • 25%
Ineffective • 25%
No improvement • 25%
Slight improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
0-10% • 25%
11-20% • 25%
21-30% • 25%
More than 30% • 25%
Less than 30% • 25%
30% to 49% • 25%
50% to 69% • 25%
70% or higher • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
